BL Kashyap & Sons Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 1, 2025, 2:43 pm

Quick Insight

BL Kashyap & Sons Ltd's current share price of ₹72.7 reflects a P/E ratio of 94.8, indicating a relatively high valuation compared to industry peers. The company's low ROE of 3.39% and ROCE of 9.61% suggest inefficient capital utilization. With a net profit of 27 crore and reserves standing at ₹501 crore, the firm's financial health seems stable, despite borrowings of ₹316 crore. However, a concerning CCC of 298 days raises questions about liquidity management. Shareholder distribution shows strong promoter holding at 61.65%, while institutional ownership by FIIs and DIIs remains minimal. The P/BV ratio of 2.21x and ICR of 1.93x warrant caution for potential investors, highlighting the need for a thorough evaluation of the company's operational efficiency and growth prospects.

Competitors of BL Kashyap & Sons Ltd

All Competitor Stocks of BL Kashyap & Sons Ltd

Quarterly Result

Last Updated: May 31, 2025, 6:49 am

Below is a detailed analysis of the quarterly data for BL Kashyap & Sons Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Sales, as of Mar 2025, the value is 294.18 Cr.. The value appears strong and on an upward trend. It has increased from 241.86 Cr. (Dec 2024) to 294.18 Cr., marking an increase of 52.32 Cr..
• For Expenses, as of Mar 2025, the value is 286.95 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 235.65 Cr. (Dec 2024) to 286.95 Cr., marking an increase of 51.30 Cr..
• For Operating Profit, as of Mar 2025, the value is 7.23 Cr.. The value appears strong and on an upward trend. It has increased from 6.21 Cr. (Dec 2024) to 7.23 Cr., marking an increase of 1.02 Cr..
• For OPM %, as of Mar 2025, the value is 2.46%. The value appears to be declining and may need further review. It has decreased from 2.57% (Dec 2024) to 2.46%, marking a decrease of 0.11%.
• For Other Income, as of Mar 2025, the value is 14.91 Cr.. The value appears strong and on an upward trend. It has increased from 8.89 Cr. (Dec 2024) to 14.91 Cr., marking an increase of 6.02 Cr..
• For Interest, as of Mar 2025, the value is 12.28 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.09 Cr. (Dec 2024) to 12.28 Cr., marking an increase of 2.19 Cr..
• For Depreciation, as of Mar 2025, the value is 3.27 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.13 Cr. (Dec 2024) to 3.27 Cr., marking an increase of 0.14 Cr..
• For Profit before tax, as of Mar 2025, the value is 6.59 Cr.. The value appears strong and on an upward trend. It has increased from 1.88 Cr. (Dec 2024) to 6.59 Cr., marking an increase of 4.71 Cr..
• For Tax %, as of Mar 2025, the value is 149.47%. The value appears to be increasing, which may not be favorable. It has increased from 40.96% (Dec 2024) to 149.47%, marking an increase of 108.51%.
• For Net Profit, as of Mar 2025, the value is -3.26 Cr.. The value appears to be declining and may need further review. It has decreased from 1.11 Cr. (Dec 2024) to -3.26 Cr., marking a decrease of 4.37 Cr..
• For EPS in Rs, as of Mar 2025, the value is -0.14. The value appears to be declining and may need further review. It has decreased from 0.05 (Dec 2024) to -0.14, marking a decrease of 0.19.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 2:42 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:46 pm

Below is a detailed analysis of the balance sheet data for BL Kashyap & Sons Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 23.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 23.00 Cr..
• For Reserves, as of Mar 2025, the value is 501.00 Cr.. The value appears strong and on an upward trend. It has increased from 474.00 Cr. (Mar 2024) to 501.00 Cr., marking an increase of 27.00 Cr..
• For Borrowings, as of Mar 2025, the value is 316.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 310.00 Cr. (Mar 2024) to 316.00 Cr., marking an increase of 6.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 676.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 606.00 Cr. (Mar 2024) to 676.00 Cr., marking an increase of 70.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 1,516.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,412.00 Cr. (Mar 2024) to 1,516.00 Cr., marking an increase of 104.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 192.00 Cr.. The value appears strong and on an upward trend. It has increased from 154.00 Cr. (Mar 2024) to 192.00 Cr., marking an increase of 38.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 2.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 1,323.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,256.00 Cr. (Mar 2024) to 1,323.00 Cr., marking an increase of 67.00 Cr..
• For Total Assets, as of Mar 2025, the value is 1,516.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,412.00 Cr. (Mar 2024) to 1,516.00 Cr., marking an increase of 104.00 Cr..

Notably, the Reserves (501.00 Cr.) exceed the Borrowings (316.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for BL Kashyap & Sons Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 1.22. This value is below the healthy minimum of 5. It has decreased from 2.33 (Mar 24) to 1.22, marking a decrease of 1.11.
• For Diluted EPS (Rs.), as of Mar 25, the value is 1.22. This value is below the healthy minimum of 5. It has decreased from 2.33 (Mar 24) to 1.22, marking a decrease of 1.11.
• For Cash EPS (Rs.), as of Mar 25, the value is 1.77. This value is below the healthy minimum of 3. It has decreased from 2.79 (Mar 24) to 1.77, marking a decrease of 1.02.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 23.23. It has increased from 22.02 (Mar 24) to 23.23, marking an increase of 1.21.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 23.23. It has increased from 22.02 (Mar 24) to 23.23, marking an increase of 1.21.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 51.17. It has decreased from 55.20 (Mar 24) to 51.17, marking a decrease of 4.03.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 4.06. This value is within the healthy range. It has decreased from 5.43 (Mar 24) to 4.06, marking a decrease of 1.37.
• For PBIT / Share (Rs.), as of Mar 25, the value is 3.51. This value is within the healthy range. It has decreased from 4.97 (Mar 24) to 3.51, marking a decrease of 1.46.
• For PBT / Share (Rs.), as of Mar 25, the value is 2.23. This value is within the healthy range. It has decreased from 2.81 (Mar 24) to 2.23, marking a decrease of 0.58.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 1.22. This value is below the healthy minimum of 2. It has decreased from 2.33 (Mar 24) to 1.22, marking a decrease of 1.11.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 1.22. This value is below the healthy minimum of 2. It has decreased from 2.33 (Mar 24) to 1.22, marking a decrease of 1.11.
• For PBDIT Margin (%), as of Mar 25, the value is 7.92. This value is below the healthy minimum of 10. It has decreased from 9.84 (Mar 24) to 7.92, marking a decrease of 1.92.
• For PBIT Margin (%), as of Mar 25, the value is 6.85. This value is below the healthy minimum of 10. It has decreased from 9.00 (Mar 24) to 6.85, marking a decrease of 2.15.
• For PBT Margin (%), as of Mar 25, the value is 4.35. This value is below the healthy minimum of 10. It has decreased from 5.08 (Mar 24) to 4.35, marking a decrease of 0.73.
• For Net Profit Margin (%), as of Mar 25, the value is 2.38. This value is below the healthy minimum of 5. It has decreased from 4.22 (Mar 24) to 2.38, marking a decrease of 1.84.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.38. This value is below the healthy minimum of 8. It has decreased from 4.22 (Mar 24) to 2.38, marking a decrease of 1.84.
• For Return on Networth / Equity (%), as of Mar 25, the value is 5.24. This value is below the healthy minimum of 15. It has decreased from 10.58 (Mar 24) to 5.24, marking a decrease of 5.34.
• For Return on Capital Employeed (%), as of Mar 25, the value is 11.60. This value is within the healthy range. It has decreased from 17.16 (Mar 24) to 11.60, marking a decrease of 5.56.
• For Return On Assets (%), as of Mar 25, the value is 1.81. This value is below the healthy minimum of 5. It has decreased from 3.72 (Mar 24) to 1.81, marking a decrease of 1.91.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.07. This value is below the healthy minimum of 0.2. It has increased from 0.06 (Mar 24) to 0.07, marking an increase of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.60. This value is within the healthy range. It has decreased from 0.62 (Mar 24) to 0.60, marking a decrease of 0.02.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.78. It has decreased from 0.91 (Mar 24) to 0.78, marking a decrease of 0.13.
• For Current Ratio (X), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 1.5. It has increased from 1.37 (Mar 24) to 1.40, marking an increase of 0.03.
• For Quick Ratio (X), as of Mar 25, the value is 1.17. This value is within the healthy range. It has increased from 0.71 (Mar 24) to 1.17, marking an increase of 0.46.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.59. This value is below the healthy minimum of 4. It has increased from 1.57 (Mar 24) to 1.59, marking an increase of 0.02.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 1.93. This value is below the healthy minimum of 3. It has decreased from 2.51 (Mar 24) to 1.93, marking a decrease of 0.58.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.19. This value is below the healthy minimum of 3. It has decreased from 2.08 (Mar 24) to 1.19, marking a decrease of 0.89.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,439.17. It has decreased from 1,822.80 (Mar 24) to 1,439.17, marking a decrease of 383.63.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has decreased from 1.46 (Mar 24) to 1.25, marking a decrease of 0.21.
• For EV / EBITDA (X), as of Mar 25, the value is 15.73. This value exceeds the healthy maximum of 15. It has increased from 14.88 (Mar 24) to 15.73, marking an increase of 0.85.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.00. This value is within the healthy range. It has decreased from 1.24 (Mar 24) to 1.00, marking a decrease of 0.24.
• For Price / BV (X), as of Mar 25, the value is 2.21. This value is within the healthy range. It has decreased from 3.12 (Mar 24) to 2.21, marking a decrease of 0.91.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.00. This value is within the healthy range. It has decreased from 1.24 (Mar 24) to 1.00, marking a decrease of 0.24.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness